An overview of nine clinical trials of salmeterol in an asthmatic population

Respiratory Medicine

Volumn 92, Issue 5, 1998, Pages 777-782

  Verberne, A A P H ^a   Fuller, R ^b  

^a Ignatius Hospital   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; METHACHOLINE; SALBUTAMOL; SALMETEROL;

ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FORCED EXPIRATORY VOLUME; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

EID: 0031839496     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(98)90012-9     Document Type: Article

References (30)

1. Hargreave FE, Dolovich J. O'Byrne PM, Ramsdale EH, Daniel EE. The origin of airway hyperresponsiveness. J Allergy Clin Immunol 1986; 78: 825-832.
2. Sterk PJ, Bel EH. The shape of the dose-response curve to inhaled bronchoconstrictor agents in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143: 1433-1437.
3. British Thoracic Society. The British guidelines on asthma management. Thorax 1997; 52 (Suppl. 1): S1-S21.
4. Britton MG, Earnshaw JS, Palmer JBD. A twelve month comparison of salmeterol and salbutamol in asthmatic patients. Eur Respir J 1992; 5: 1062-1067.
5. Lundback B, Rawlinson DW, Palmer JBD. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax 1993; 48: 148-153.
6. Brogden RN, Faulds D. Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airway disease. Drugs 1991; 42: 895-912.
7. 2-adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 1988; 43: 674-678.
8. Campos Gongora H, Wisniewski AFZ, Tattersfield AE. A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects. Am Rev Respir Dis 1991; 144: 626-629.
9. Derom EY, Pauwels RA, van der Straeten MEF. The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours. J Allergy Clin Immunol 1992; 89: 811-815.
10. Twentyman OP, Finnerty JP, Harris A, Palmer J, Holgate ST. Protection against allergen-induced asthma by salmeterol. Lancet 1990; 336: 1338-1342.
11. Malo JL, Ghezzo H, Trudeau C, L'Archevêque J, Cartier A. Salmeterol, a new inhaled beta-2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. J Allergy Clin Immunol 1992; 89: 567-574.
12. Green GP, Price JF. Prevention of exercise-induced asthma by inhaled salmeterol xinafoate. Arch Dis Child 1992; 67: 1014-1017.
13. Dahl R, Pedersen B, Venge P. Bronchoalveolar lavage studies. Eur Respir Rev 1991; 1: 272-275.
14. Baker AJ, Fuller RW. Anti-inflammatory effect of salmeterol on human alveolar macrophages. Am Rev Respir Dis 1990; 141 (Suppl.): A394.
15. Butchers PR, Cousins SA, Vardey CJ. Salmeterol: a potent and long-acting inhibitor of the release of inflammatory and spasmogenic mediators from human lung. Br J Pharmacol 1987; 92 (Suppl.): 745P.
16. Beach JR, Young CL, Harkawat R, Gardiner PV, Avery AJ, Coward GA, Walters EH, Dendrick DJ. Effect on airway responsiveness of six weeks treatment with salmeterol. Pulm Pharmacol 1993; 6: 155-157.
17. Booth H, Fishwick K. Harkawat R, Devereux G, Hendrick DJ, Walters EH. Changes in methacholineinduced bronchoconstriction with the long-acting /?2-agonist salmeterol in mild to moderate asthmatic patients. Thorax 1993; 48: 1121-1124.
18. Booth H, Bish R, Walters J, Whitehead F, Walters EH. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 1996; 51: 1100-1104.
19. Cheung D, Timmers MC, Zwinderman AH, Bel EH, Dijkman JH, Sterk PJ. Long-term effects of a longacting /?2-adrenoceptor agonist, salmeterol, on airway responsiveness in patients with mild asthma. N Eng! J Med 1992; 327: 1198-1203.
20. Leegard J, Olshot K, Carlsen K-H, Bratten G. Does inhaled salmeterol influence bronchial hyperresponsiveness in asthmatic children? Eur Respir J 1994; 7 (Suppl. 18): 422.
21. Meijer GG, Postma DS, Mulder PGH. Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids. Am J Respir Crû Care Med 1995; 152: 1887-1892.
22. Roberts JA, Bradding P, Holgate ST, Howarth PH. Effects of a six week course of salmeterol on bronchial reactivity. Thorax 1992; 47: 230P.
23. Verberne AAPH, Hop WCJ, Creyghton FBM et al Airway responsiveness after a single dose of salmeterol and during 4 months of treatment in asthmatic children. J Allergy Clin Immunol 1996; 97: 938-946.
24. Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108: 1235-1239.
25. Kalra S, Swystun VA, Bhagat R, Cockcroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996; 109: 953-956.
26. Yates DH, Sussman HS, Shaw MJ, Barnes PJ, Chung KF. Regular formoterol treatment in mild asthma. Am J Respir Crit Care Med 1996; 152: 1170-1174.
27. Kraan J, Koeter GH, van den Mark TW, Sluiter HJ, de Vries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 1985; 76: 628-636.
28. Kerrebijn KF, van Essen-Zandvliet EEM, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987; 79: 653-659.
29. Bel EH, Timmers MC, Zwinderman AH, Dijkman JH, Sterk PJ. The effect of inhaled corticosteroids on the maximal degree of airway narrowing to methacholine in asthmatic subjects. Am Rev Respir Dis 1991; 143: 109-113.
30. Nelson HS, Szefler SJ, Martin RJ. Regular inhaled beta-adrenergic agonists in the treatment of bronchial asthma: beneficial or detrimental? Am Rev Respir Dis 1991; 144;: 249-250.